Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile
Go back to Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile| Isilon Systems, Inc. (NASDAQ: SLN) | Delayed: 11.36 +0.18 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.18 | 52 Week High | $0.27 | |||
| Open | $11.13 | 52 Week Low | $0.18 | |||
| Day High | $11.42 | P/E | N/A | |||
| Day Low | $11.01 | EPS | $-0.44 | |||
| Volume | 371,181 | |||||
